[2026] Participation in the Spring Scientific Conference of the Korean Neurological Association

Bredis Healthcare participated in the 2026 Spring Conference of the Korean Neurological Association, held on Saturday, April 4, 2026, to review the latest trends in bioanalytical technology and showcase its core solutions.

At the conference, through booth operations and networking, the company highlighted the research and clinical application potential of its ultra-sensitive biomarker analysis platform, SIMOA, and its multiplex analysis technology, NULISA.

SIMOA enables the quantification of ultra-trace biomarkers at the femtogram (fg/mL) level based on sensitivity over 1,000 times higher than conventional ELISA, while NULISA is a solution that effectively reduces time and sample consumption by simultaneously analyzing multiple biomarkers in a single experiment.

In particular, researchers showed high interest in the analysis of trace biomarkers—which were difficult to detect using conventional methods—and inquiries regarding the potential for actual research and clinical applications followed.

Bredis Healthcare will continue to strengthen its competitiveness in the field of precision bioanalysis through ongoing participation in academic conferences and collaboration.